Abstract

Background

Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.

Methods

We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.

Results

Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.

Conclusions

The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.

中文翻译：

---

严重急性呼吸综合征冠状病毒 2 单克隆抗体联合治疗 2019 年冠状病毒病和原发性抗体缺乏症患者的治疗

摘要

背景

先前的报告强调了严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 特异性单克隆抗体 (mAb) 对 2019 年冠状病毒病的疗效。

方法

我们对原发性抗体缺陷的 SARS-CoV-2 感染患者的标准护理治疗中添加 mAb 的临床结果和抗病毒作用进行了前瞻性研究。

结果

8 名接受 mAb 治疗的患者（22 天）出现 SARS-CoV-2 定量聚合酶链反应（qPCR）阳性的中位时间比仅接受标准护理治疗的 10 名患者（37 天，P = 0.026）短。mAb 给药后 SARS-CoV-2 qPCR 阳性的中位时间为 10 天。

结论

SARS-CoV-2 mAbs 治疗对一抗缺陷患者有效且耐受性良好。